Celecoxib

Name: Celecoxib
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (41 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

41 publications

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib has been cited by 41 publications

J Clin Invest, 2020, 26;132417

PubMed: 32452837 ( click the link to review the publication )

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Cells, 2020, 14;9(5):E1222

PubMed: 32423044 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Brain Res, 2020, 20;1740:146846

PubMed: 32325074 ( click the link to review the publication )

AAPS PharmSciTech, 2020, 17;21(5):135

PubMed: 32419073 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )
Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	NH7kVndHfW6ldHnvckBCe3OjeR?=	MVewMlEuOzBizszN	NEmy[WI1QCCq		MmDibY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw>	M1fXWVI3PTF\|MUey
H460	Ml:ySpVv[3Srb36gRZN{[Xl?	MoLNNE4yNTNyIN88US=>	M1vHNlQ5KGh?		MULpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	NIXBUWwzPjVzM{G3Ni=>
HKESC-2	NF;ZcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\QNYhsOjEEoN88US=>	NY[0VIdLPDkEoHlCpC=>		NWnKZ4k6e2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi	M{D6PFI3PDd2Nkmz
CaES-17	NXjnS2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWyNOKh\|ryP	M{n0fFQ5yqCqwrC=		M2[2d5Nq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>?	MnTINlY1PzR4OUO=
HKESC-2	NGjhPGdCeG:ydH;zbZMhSXO\|YYm=	Ml;wNlDDqM7:TR?=	MYC0POKhcMLi		M17BSpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>	NXT4bI5HOjZ2N{S2PVM>
CaES-17	NEHOSWxCeG:ydH;zbZMhSXO\|YYm=	M3fRelIxyqEQvF2=	NFnOSJk1QMLiaNMg		MmDRdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=>	NFf4dHIzPjR5NE[5Ny=>
A549	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[1MVE3OCEQvF2=	NVrOdXNyPDkEoHlCpC=>	M4jhVGROW09?	MlXwTWM2OD1zNkOuOEDPxE1?	Ml;TNlY1PjR4NEO=
HCC827	NUPH[4FPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rYeVUuOTZyIN88US=>	MlnuOFjDqGkEoB?=	MXnEUXNQ	MXfJR\|UxRTZ7LkKg{txO	MlXONlY1PjR4NEO=
A549	NGLIe\|hCeG:ydH;zbZMhSXO\|YYm=	MoLKPFAhyrWP	NF7DXZA1QMLiaNMg	Ml20SG1UVw>?	MnvUbY5lfWOnczDhdI9xfG:\|aYO=	MVSyOlQ3PDZ2Mx?=
HCC827	M3TsdmFxd3C2b4Ppd{BCe3OjeR?=	M324NVgxKML3TR?=	M3zYUVQ5yqCqwrC=	NVXFOJA2TE2VTx?=	NGHobGNqdmS3Y3XzJIFxd3C2b4Ppdy=>	NVvKW3lROjZ2NkS2OFM>
SGC-7901/DDP	MkXzSpVv[3Srb36gRZN{[Xl?	M2qz[lExyqEEtV2=	NHvrNnAzPCCq		M1LaRYlvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44>	MnjQNlY1ODd4NUO=
SGC-7901	NEHUc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3YNlTDqGkEoB?=		M1u5S2lEPTB;MUG1MlA5KM7:TR?=	NGmwS3EzPjRyN{[1Ny=>
SGC-7901/DDP	NEWzN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnLHNlTDqGkEoB?=		Mn;PTWM2OD1\|NT60OUDPxE1?	MnTPNlY1ODd4NUO=
SGC-7901/DDP	M2jySWFxd3C2b4Ppd{BCe3OjeR?=	MUSxNOKhyrWP	NVPuU3o3OjRiaB?=		NF7HSGhqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m\|cHzheIlv	NFi0RYMzPjRyN{[1Ny=>
SGC-7901/DDP	NXfifG0xTnWwY4Tpc44hSXO\|YYm=	Mmr1NVDDqML3TR?=	NWTkb4lQOjRiaB?=		NVTSNZd3cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC=	NWHPS2pkOjZ2MEe2OVM>
SGC-7901/DDP	NIC3V2tHfW6ldHnvckBCe3OjeR?=	MlT6NVDDqML3TR?=	Mn7ENlQhcA>?		NI\1WZVk[XW\|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4>	MYiyOlQxPzZ3Mx?=
H357	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLKO{42NzFyIN88US=>	NEXEUlQ1QCCq	M1LQVGROW09?	MXrpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4	M2PNTVI3ODB7OEe0
TAF	M3XJcmZ2dmO2aX;uJGF{e2G7	NVHZRXQxOTEEoNM1US=>	NUD4NVRrPyCm		NFf0fIZi\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?=	M1zTO\|I2QTh5MUK3
TAF	M{XKTmZ2dmO2aX;uJGF{e2G7	NEHaU4EyOMLiwsXN	NEHDcXY{OC1zMkCgcYlv		NGTlbpRxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26\|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc>	MUOyOVk5PzF{Nx?=
TAF	M{\5ZWZ2dmO2aX;uJGF{e2G7	MVqxNOKhyrWP	MoLnOFghcA>?		MoCybY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	NYDGeXRDOjV7OEexNlc>
PANC-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXqyNE83OC9zMECg{txO	M{HGPVI1NzR6L{eyJIg>		M2TyR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NVviRWIzOjV7N{OwOlI>
PANC-1	NX3XbHNKTnWwY4Tpc44hSXO\|YYm=	NYDWPFI2OjBxNkCvNVAxKM7:TR?=	NYPTWWpsOjRiaB?=		MWnheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	M{jhOVI2QTd\|ME[y
HeLa	NFvrOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHiU5RkOjEEoN88UeKh	NEHmNoszPMLiaB?=		MmfS[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25?	NH\NfVczPTd5MESyNy=>
SACC-83	NH\XOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOyNOKh\|ryPwrC=	NVeyUGtyOjUEoHi=		MlHl[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25?	NGize3EzPTd5MESyNy=>
HeLa	NILoc5BCeG:ydH;zbZMhSXO\|YYm=	NF64NYQzOMLizszNxsA>	NUfJcGVNOjUEoHi=		M3PETIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM>	M4TzU\|I2PzdyNEKz
SACC-83	MmruRZBweHSxc3nzJGF{e2G7	NELjZokzOMLizszNxsA>	NXLNOGt{OjUEoHi=		MnXz[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=>	MVuyOVc4ODR{Mx?=
HeLa	NV7RVIF6TnWwY4Tpc44hSXO\|YYm=	M{HHT\|IxNzRyL{iwJO69VQ>?	MnL2NlTDqGh?		NF7hemJ2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW\|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>?	NYH5e4xsOjV5N{C0NlM>
SACC-83	M13jWmZ2dmO2aX;uJGF{e2G7	MWmyNE81OC96MDFOwG0>	NGDVcVAzPMLiaB?=		NEi5bWp2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW\|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>?	NVXGNpRnOjV5N{C0NlM>
HLCZ01	M3fr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYew5qCUPjEEoNM1US=>	Moj1OFghcA>?	M1vqNWROW09?	MoXCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NV;uc2x1OjV5MkS4PVk>
HLCZ01	NVTHNFVxTnWwY4Tpc44hSXO\|YYm=	Ml;kOFDDqM7:TR?=	MV[yOEBp	NEDQd5lFVVOR	NV;lRmN5cW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	MXSyOVczPDh7OR?=
HLCZ01	M{HZS2Fxd3C2b4Ppd{BCe3OjeR?=	NWfnepFmPDEEoN88US=>	MlXENlQhcA>?	MUfEUXNQ	NEK0TJpmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u\|rF?	NYj2OYpSOjV5MkS4PVk>
HLCZ01	MnfhSpVv[3Srb36gRZN{[Xl?	M1n4U\|QxyqEQvF2=	MUmyOEBp	MYjEUXNQ	M1\CXYlv[3KnYYPld{BVWkGLTDDlfJBz\XO\|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=>	NGC1cnIzPTd{NEi5PS=>
MGC803	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2eycFAuPjBizszN	NYXRboJ{PzJiaB?=		NHrYd2xKSzVyPUS3MlI26oDLwsJihKk3NjR\|IN88US=>	MX:yOVcxOTN5OB?=
SGC7901	M{PGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPjbXUyOC14MDFOwG0>	MoD2O\|IhcA>?		NUPCVnNKUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0>	M4fLeVI2PzBzM{e4
MGC803	NGjldlVHfW6ldHnvckBCe3OjeR?=	MmTtOFDDqM7:TR?=	M{fPSFgwOTZxMkSgbC=>		M{PQPZVxemWpdXzheJMhS2KuLXKg[ZhxemW\|c3nvci=>	MVWyOVcxOTN5OB?=
SGC7901	MWnGeY5kfGmxbjDBd5NigQ>?	MnnkOFDDqM7:TR?=	M1XKdlgwOTZxMkSgbC=>		M3\HOJVxemWpdXzheJMhS2KuLXKg[ZhxemW\|c3nvci=>	M4LLWlI2PzBzM{e4
MCF-7	M{C1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLYTI8yNzFyIN88US=>	NFPXZoY4OiCq	MV3EUXNQ	NFnVdFNmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	M4\IRVI2PjZ5NUGw
MDA-MB-231	NEXqbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LJOlEwOTBizszN	NV\VdINHPzJiaB?=	NXzM[G4xTE2VTx?=	NFvSTXdmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	MV6yOVY3PzVzMB?=
MDA-MB-231	NXuwXVBFTnWwY4Tpc44hSXO\|YYm=	NVzLZ5hrOC12MDFCuW0>	M2fTclQuOjRiaB?=		NXjDTYRFcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MmPkNlU2QDd\|Mkm=
MCF-7	Mn76SpVv[3Srb36gRZN{[Xl?	Mmq2NE01OCEEtV2=	NGf1T281NTJ2IHi=		NHvyclVmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS\|Ih\XiycnXzd4lwdsLi	MWOyOVU5PzN{OR?=
MCF7-MX	NHXNU5FHfW6ldHnvckBCe3OjeR?=	NXHaTFdHOC12MDFCuW0>	MWG0MVI1KGh?		NIXZZVlmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS\|Ih\XiycnXzd4lwdsLi	Ml62NlU2QDd\|Mkm=
MDA-MB-231	NGf4[Y9HfW6ldHnvckBCe3OjeR?=	M134WVAuPDBiwsXN	MlPGOE0zPCCq		NInuVW5{fGmvdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC=	NIXWVJczPTV6N{OyPS=>
A2780	NF;ufmlHfW6ldHnvckBCe3OjeR?=	NXH4TW96PS9zMD:xOUDPxE1?	MVq0PEBp		M1noRoRm[3KnYYPld{BEd3hvMjDlfJBz\XO\|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MVWyOVQzPDh7OB?=
SKOV3	MnrySpVv[3Srb36gRZN{[Xl?	NWnBOVdjPS9zMD:xOUDPxE1?	MYK0PEBp		M{nSb4Rm[3KnYYPld{BEd3hvMjDlfJBz\XO\|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NU\6[FlxOjV2MkS4PVg>
A2780	MXPGeY5kfGmxbjDBd5NigQ>?	NFHIcXk2NzFyL{G1JO69VQ>?	M3HUeFQ5KGh?		M3fPdYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	NV3ue\|BiOjV2MkS4PVg>
SKOV3	NEL3WG9HfW6ldHnvckBCe3OjeR?=	MmTYOU8yOC9zNTFOwG0>	M2DMclQ5KGh?		NIfCc\|BmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw	MnfLNlU1OjR6OUi=
A2780	NXHJR3BHTnWwY4Tpc44hSXO\|YYm=	MWm1M\|ExNzF3IN88US=>	MWO0PEBp		NWDUVGt{\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu	NXvWSIdmOjV2MkS4PVg>
SKOV3	NIH4eYdHfW6ldHnvckBCe3OjeR?=	M4G0SlUwOTBxMUWg{txO	M1;pTlQ5KGh?		MYfk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?	NVTUfYtyOjV2MkS4PVg>
A2780	NIXsZZJHfW6ldHnvckBCe3OjeR?=	MlXDOU8yOC9zNTFOwG0>	NFjKdWIyKGh?		MV7pcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MXqyOVQzPDh7OB?=
SKOV3	NIXCdY9HfW6ldHnvckBCe3OjeR?=	NYD5fHBMPS9zMD:xOUDPxE1?	NYf2PWhWOSCq		NHy2fWhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1jsOlI2PDJ2OEm4
HCT-15	MYfGeY5kfGmxbjDBd5NigQ>?	NWfrOoNSOTBvNUCg{txO	NVvQXXRHPi1\|NjDo		M1X4N4lv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MU[yOVIyQDB{OB?=
HT-29	NXvDTmFUTnWwY4Tpc44hSXO\|YYm=	MnvnNVAuPTBizszN	NW\GSZFPPi1\|NjDo		MXLpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	Mkf0NlUzOThyMki=
HSC3	MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MlfXNQKBmzRyIN88US=>	MmDpOFghcA>?		NV;Cd41QUUN3ME2yOU42yrFzLke4NEDPxE1?	NYPaZWFXOjVzOUi3PFk>
HSC3	NFLXfphCeG:ydH;zbZMhSXO\|YYm=	MoXVNlUh\|ryP	MnSyOFghcA>?		MkjDbY5lfWOnczDhdI9xfG:\|aYO=	MorhNlUyQTh5OEm=
HSC3	NGTVOFVHfW6ldHnvckBCe3OjeR?=	NIfCVnUzPSEQvF2=	M3\3U\|Q5KGh?		NETSWGxmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW	NHvUWXIzPTF7OEe4PS=>
HSC3	M{\NfWZ2dmO2aX;uJGF{e2G7	M{fZ[\|I2KM7:TR?=	M3PIbVQ5KGh?		NGfTTnVqdmirYnn0d{BJW0N\|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ>	NEHYN\|kzPTF7OEe4PS=>
HSC3	MYnGeY5kfGmxbjDBd5NigQ>?	MXWyOUDPxE1?	NFz0N\|M4OiCq		NXrI[Zho\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh	MX2yOVE6QDd6OR?=
201T	NX3Fc21KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUXIS4lCPzJiaB?=	NX\hd\|J[TE2VTx?=	NIq5[m9KSzVyPUS4MlYhyrWP	NILP[5kzPTB3N{m0NS=>
273T	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHnTfmQ4OiCq	NYjXPG52TE2VTx?=	NEDsSm5KSzVyPUiwMlUhyrWP	NFraZY0zPTB3N{m0NS=>
Hep-2	NXnhW\|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\SN\|AwPTBxMUCwJO69VQ>?	NFzHbGQyOi9{ND:zOk81QCCq	NID0eotFVVOR	MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NHz6RpczPDl7OEW2OC=>
Hep-2	MYPBdI9xfG:\|aYOgRZN{[Xl?	NEXGPFY2OCEQvF2=	MXywMVQ5KGh?	M3rCVGROW09?	NXmzNVBycW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MViyOFk6QDV4NB?=
Hep-2	MUjGeY5kfGmxbjDBd5NigQ>?	NI\tVYU2OCEQvF2=	M1vGZlAuPDhiaB?=	NYDBUpZTTE2VTx?=	NFy5[5dz\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?=	NGi0[YQzPDl7OEW2OC=>
Hep-2	NXn6O4VXTnWwY4Tpc44hSXO\|YYm=	M2\VZ\|UxKM7:TR?=	M2HsblAuPDhiaB?=	MkDJSG1UVw>?	NFyzPXhl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>?	MWOyOFk6QDV4NB?=
SGC-7901	NWnISnliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWmxNE82OC9zMECg{txO	MWiyOE81QC95MjDo	NUXQfGJYTE2VTx?=	MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MojvNlQ6QTJ7NUi=
MKN-45	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnVSmoyOC93MD:xNFAh\|ryP	Mo\oNlQwPDhxN{KgbC=>	MUTEUXNQ	NUTVWnlncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M2fJXlI1QTl{OUW4
SGC-7901	M2TyfmZ2dmO2aX;uJGF{e2G7	NULCUpJmOTBxNUCvNVAxKM7:TR?=	NH7XVGQ1QCCq	NEXFWYVFVVOR	NYXneJI{\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO\|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MkfNNlQ6QTJ7NUi=
MKN-45	M33PSWZ2dmO2aX;uJGF{e2G7	NXfjN4l[OTBxNUCvNVAxKM7:TR?=	MkDmOFghcA>?	MkTWSG1UVw>?	MojS[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NF;xclczPDl7Mkm1PC=>
C666-1	Mo\3R5l1d3SxeHnjbZR6KEG\|c3H5	MYGyNE05OCEQvF2=	M{DOV\|I1KGh?		NYnkRXc6\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	Mkn3NlQ5PTR6M{i=
CNE-1	NFW0fJVEgXSxdH;4bYNqfHliQYPzZZk>	NYTNWm1wOjBvOECg{txO	NIHnNZYzPCCq		NGfz[\|Nl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	NYfONlZuOjR6NUS4N\|g>
CNE-2	NIj1TXlEgXSxdH;4bYNqfHliQYPzZZk>	NF3YdFAzOC16MDFOwG0>	NW\LOZN4OjRiaB?=		NWLLNXN4\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	MX:yOFg2PDh\|OB?=
C666-1	MVjDfZRwfG:6aXPpeJkhSXO\|YYm=	Mn\SOlAh\|ryP	MWm3JIQ>		MW\lcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?=	M2fCfFI1QDV2OEO4
CNE-1	M13qTGN6fG:2b4jpZ4l1gSCDc4PhfS=>	NUPQSI9mPjBizszN	MoLZO{Bl		NGHjWpNmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=>	M2LRfFI1QDV2OEO4
SNU-1041	M4HTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvI[oYxNTRyIN88US=>	Mln2OFghcA>?		Mlj0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NVO0VXE{OjR4OUK3NFM>
SNU-1041	Mo\iSpVv[3Srb36gRZN{[Xl?	NXXlVVVDOjBxM{Cg{txO	M1TVWFQhcA>?		MXLpcoR2[2W\|IHX4dJJme3Orb36gc4bDqEOKT2CsJGdTWDd6wrDhcoTDqFiEUEJCpIF1KHSqZTDSUmEhdGW4ZX\|CpC=>	Mni5NlQ3QTJ5MEO=
SNU-1041	M3ywVGZ2dmO2aX;uJGF{e2G7	NH;4[4ExNTRyIN88US=>	Mny4OEBp		NGHodW52eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?=	MmTtNlQ3QTJ5MEO=
SGC-7901	NFTJ[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DlV\|UxNTF{NTFOwG0>	NH34dFgzPC92OD:3NkBp		M2\YNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NGq4Zm8zPDZ5NkO5OC=>
SGC-7901	NIrTSHpCeG:ydH;zbZMhSXO\|YYm=	NHjpTmUyODBizszN	MnrPO\|IhcA>?		M1zmcIlv\HWlZYOgZZBweHSxc3nz	M3fvd\|I1Pjd4M{m0
SGC-7901	MX;GeY5kfGmxbjDBd5NigQ>?	NF7yeGo4PS9zMECvNVI2KM7:TR?=	M372OFI1NzR6L{eyJIg>		M3z1Zolv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy	MlPBNlQ3PzZ\|OUS=
LMeC	M2OyTGZ2dmO2aX;uJGF{e2G7	MlP5NlAwPTBizszN	M3\EN\|Q5KGh?		M332SIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw	NIPDfmEzPDZ3Nke0Oi=>
CMeC-1	NIfjVlFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1ficFIxNzVyIN88US=>	NU\M[4JXPDhiaB?=		NXv3To9mcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MUeyOFY2Pjd2Nh?=
LMeC	M4n2SGNmdGxiVnnhZoltcXS7IFHzd4F6	M1zLU\|IxNzVyIN88US=>	M4LZdlQ5KGh?		M3HKS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MV6yOFY2Pjd2Nh?=
CMeC-1	MV3GeY5kfGmxbjDBd5NigQ>?	NEfMUnkzOC93MDFOwG0>	M{S0SFQ5KGh?		NUL3UmhYcW6mdXPld{BIOS2VIHHydoV{fA>?	MY[yOFY2Pjd2Nh?=
LMeC	MV3GeY5kfGmxbjDBd5NigQ>?	MWOyNE82OCEQvF2=	NYjUSZlbPDhiaB?=		NXrnXY1zcW6mdXPld{BIOS2VIHHydoV{fA>?	NUTyeZl4OjR4NU[3OFY>
CMeC-1	M3rPd2Z2dmO2aX;uJGF{e2G7	M{TC[\|IxNzVyIN88US=>	Mm\uOFghcA>?		Mny1[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlrhNlQ3PTZ5NE[=
LMeC	M4PpbmZ2dmO2aX;uJGF{e2G7	NIfvO\|IzOC93MDFOwG0>	Mnn2OFghcA>?		NETiN3ll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M{[1XFI1PjV4N{S2
CMeC-1	NEPRbVZHfW6ldHnvckBCe3OjeR?=	MV2yNE82OCEQvF2=	NUj0dW9jPDhiaB?=		MmjGbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	M{D0dFI1PjV4N{S2
LMeC	MnW3SpVv[3Srb36gRZN{[Xl?	M170OFIxNzVyIN88US=>	M{fITlQ5KGh?		M2THSolv\HWlZYOgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44>	NEPSVWEzPDZ3Nke0Oi=>
OVCAR-3	MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MX[xNEDDvU1?	MXKxJIg>		MWLlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg	NXjjfmwxOjR3MkCyNlc>
OVCAR-3	NVv2PIRvSXCxcITvd4l{KEG\|c3H5	MljHNVAhyrWP	NYTIToR3OSCq		MWHwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA>	MXiyOFUzODJ{Nx?=
OVCAR-3	MWjGeY5kfGmxbjDBd5NigQ>?	MX6xNEDDvU1?	NUXj[2k6OSCq		MW\lcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?=	MX6yOFUzODJ{Nx?=
OVCAR-3	MX3GeY5kfGmxbjDBd5NigQ>?	M2nHblExKML3TR?=	M17SV\|EhcA>?		NECwfXhld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw>	MVqyOFUzODJ{Nx?=
OVCAR-3	MkTSSpVv[3Srb36gRZN{[Xl?	NXK2ZoxzOTBiwsXN	NGLyT2kyKGh?		MofCbY5pcWKrdIOgdIFkdGm2YYjlcE1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44>	MWGyOFUzODJ{Nx?=
CF33	M{XkeGZ2dmO2aX;uJGF{e2G7	MWexNFAh\|ryP	MkLiNlQhcA>?		NHXhOWxqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?=	NILSZXozPDVyM{e4Ni=>
CF33	M4K0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHe5UmkyOC1zMECg{txO	NU\QflhxOC12IHS=		MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFzqPVAzPDVyM{e4Ni=>
CF33	M1rhdWZ2dmO2aX;uJGF{e2G7	Mly2NVAuOTByIN88US=>	NW\ERYpzPC1{NDDo		M4DJNoRm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy\|IHnuJGcxN0dzIHHydoV{fA>?	Mn\QNlQ2ODN5OEK=
LNCaP	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXf6[29FOi93L{GwJO69VQ>?	MV[5OkBp		MoHDbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?=	NGnmU2gzPDJ7Nkm3PC=>
LNCaP	NHXkSFFCeG:ydH;zbZMhSXO\|YYm=	NYXYUmZVOi93L{GwJO69VQ>?	MUO5OkBp		NEniclZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	NXjy[\|A6OjR{OU[5O\|g>
PC-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[wMVUxKM7:TR?=	M1T6b\|Q56oDLaB?=		MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MnjxNlQyOjd6OEK=
PC-3	Ml61R4VtdCCYaXHibYxqfHliQYPzZZk>	NYjQNnNpOC1zMECg{txO	MmTkO\|IhcA>?		MUjk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NXTVVZV1OjRzMke4PFI>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SC 58635
Smiles	CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S](N)(=O)=O)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2
NCT03643744	Recruiting	Drug: Celecoxib 200mg\|Drug: Placebo	Actinic Keratosis\|Photodynamic Therapy	Jeffrey B. Travers MD PhD\|Wright State Physicians	April 1 2019	Phase 1
NCT01344200	Not yet recruiting	Drug: Celecoxib	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	March 2019	Phase 4
NCT02876094	Recruiting	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03672162	Recruiting	Procedure: Total abdominal hysterectomy	Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib	Rajavithi Hospital	September 1 2018	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Rofecoxib

Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib